-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 10, 2024

Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

Episodes in this series

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 9 Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 10 Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"

EP. 11 The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"

EP. 12 Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 13 Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

August 3rd 2026

Brittany Craiglow, MD in part 1 of an AJMC Q&A

The Psychiatric Burden of Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

BySkylar Jeremias,Brittany G. Craiglow, MD, FAAD

August 3rd 2026

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Peptide vial | Image credit: Iurii - stock.adobe.com

FDA Panel Backs 6 Peptides for Compounding

ByPearl Steinzor

July 31st 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%